5.1. screening individual early detection. diagnostic pathway pca aims timely detection significant pca, leaving insignificant pca undetected, balancing diagnostic accuracy burden individual healthcare provider. patient-specific factors lower urinary tract symptoms (luts), family history, age, comorbidity always considered. men may enter diagnostic pathway different indications, including clinical symptoms, opportunistic early detection (individual), screening (population-based). prevalence pca significant pca different dependent indication, resulting different yields subsequent diagnostic pathway. 5.1.1. clinical symptoms localised pca usually asymptomatic. local progression may cause symptoms luts, erectile dysfunction (ed), retention, pain, haematuria. bone metastases may cause pain spinal cord compression. digital rectal examination (dre) psa usually part initial diagnostic work-up cases, diagnostic algorithm may initiated. definitive diagnosis normally depends histopathological verification prostate biopsy cores. however, men high suspicion malignancy (e.g. malignant feeling prostate, psa >100 ng/ml positive bone scan might avoid biopsy especially pre-existing comorbidities would exclude second-line treatments. 5.1.2. individual early detection early detection may initiated individual level. men risk factors include age > 50 years; men 45 years age family history pca; men african descent 45 years age; men carrying brca2 mutations 40 years age . risk detecting clinically insignificant cancers possible overtreatment discussed along possibility improved disease-specific mortality. difficult accurately estimate individual benefit harm due early detection individual man effect may larger diluting effects intention-to-treat analyses screening trials applicable (i.e. non-participation: participation screening invitation; contamination: screening occurring control arm) . nevertheless, comparison systematic opportunistic screening suggested over-diagnosis mortality reduction systematic screening group compared higher over-diagnosis marginal survival benefit, best, opportunistic screening regimen . baseline psa may used predict pca mortality fifteen twenty yrs. follow-up intervals two years may offered initially risk (psa > 1 ng/ml 40 years; psa > 2 ng/ml 60 years) . age attempts early diagnosis stopped remains controversial, individual’s life expectancy must definitely taken account. men less fifteen-year life expectancy unlikely benefit, based data prostate cancer intervention versus observation trial (pivot) european randomized screening prostate cancer (erspc) trials. furthermore, although simple tool evaluate individual life expectancy, co-morbidity least important age. detailed review found section 6.1 ‘estimating life expectancy health status’ siog guidelines . informed men one risk factors above, life expectancy > fifteen years requesting investigation given psa test undergo dre, diagnostic algorithm may initiated . figure 5.1 presents flow diagram deciding prostate biopsy * psa >50, ct3-4** mri available / possible 5.1.3. population-based screening population mass screening defined ‘systematic examination asymptomatic men identify individuals risk specific disease’ usually initiated health authorities. co-primary objectives are: reduction mortality due pca;a maintained quality life (qol) expressed qol-adjusted gain life years (qalys). screening pca remains one controversial topics urological literature . cochrane review randomised pca screening trials pca mortality endpoint published 2013 updated 2018 . main findings updated publication results five rcts, randomising 721,718 men, are: screening associated increased diagnosis pca (incidence ratio [ir]: 1.23 95% ci: 1.03–1.48).screening associated detection localised disease (rr: 1.39, [1.09–1.79]) less advanced pca (t3–4, n1, m1; rr: 0.85 [0.72–0.99]).no pca-specific survival benefit observed (ir: 0.96 [0.85–1.08]). main endpoint trials.no overall survival (os) benefit observed (ir: 0.99, 95% ci: 0.98–1.01). none trials designed/powered endpoint. included studies different regarding multiple aspects including trial size, time periods, age groups, participation/compliance rates, previous screening rates (opportunistic testing control arm, ‘contamination’), one-time vs. repeat screening, applied diagnostic pathway. differences account discrepancies results single studies cochrane review aggregated findings. erspc study started early 90’s, included >182,000 european men, found significant reduction pca mortality due screening. erspc applied mainly psa-based screening protocol (cut-off 3.0–4.0 ng/ml followed systematic sextant prostate biopsy, every two four years men aged 50–74) contamination rate relatively low compared large studies prostate lung colorectal ovarian (plco) screening trial . limitation heterogeneity patient groups applied screening protocols. since 2013, data updated sixteen years follow-up . extended follow-up, mortality reduction (21% 29% non-compliance adjustment) remains unchanged. however, number needed screen (nns) treat decreasing nns observed breast cancer trials (table 5.1). table 5.1: follow-up data erspc study years follow-upnumber needed screennumber needed treat91,41048119793513781271657018 rotterdam section erspc, 21 years follow-up, risk ratio death due pca 0.73 screening group, number needed invite 246 number needed diagnose (nnd) fourteen prevent one death due pca . prevent one metastasized case nns 121 nnd seven. goteborg screening trial, eighteen years follow-up, ratio death pca screening group compared control group 0.65 (95% ci: 0.49–0.87) men starting screening age 55–59 0.47 (95% ci: 0.29–0.78) . number needed invite 231; nnd ten. benefit screening reducing pca-specific mortality (pcsm) even favourable impact metastases rates, counter-balanced side effects screening increased diagnosis rates, led over-treatment low-risk pca, subsequent treatment-related side-effects . regarding qol, beneficial effects screening side effects seem balance out, resulting limited overall impact invited population . recognition harms over-diagnosis over-treatment led redesign pathway early detection pca including identification specific risk groups, individualised re-testing interval, improved indication biopsy using risk calculators and/or mri, targeted biopsies, application low-risk disease. negative screening, psa measurement dre need repeated , optimal intervals psa testing dre follow-up unknown varied several prospective screening trials. risk-adapted strategy might consideration, based initial psa level. men baseline psa < 1 ng/ml 40 years < 2 ng/ml 60 years decreased risk pca metastasis death pca several decades later . retesting interval therefore every two years initially increased risk postponed eight years low-risk . analysis erspc data supports recommendation eight-year screening interval men initial psa concentration < 1 ng/ml; fewer 1% men initial psa concentration < 1 ng/ml found concentration biopsy threshold 3 ng/ml four-year follow-up; cancer detection rate eight years close 1% . long-term survival qol benefits extended psa re-testing (every eight years) remain proven population level. 5.1.4. screening patients brca mutations impact study evaluates targeted pca screening using psa men aged 40–69 years germline brca1/2 mutations (annually, biopsy recommended psa > 3.0 ng/ml). three years screening, brca2 mutation carriers associated higher incidence pca, younger age diagnosis, clinically significant tumours compared non-carriers . influence brca1 mutations pca remained unclear. differences age tumour characteristics detected brca1 carriers brca1 non-carriers. mismatch repair cohort impact men msh2 msh6 pathogenic variants found higher incidence significant pca vs. non-carriers . 5.1.5. guidelines individual early detection recommendationsstrength ratingdo subject men prostate-specific antigen (psa) testing without counselling potential risks benefits.strongoffer individualised risk-adapted strategy early detection well-informed man life-expectancy least fifteen years.weakoffer early psa testing well-informed men elevated risk pca:men 50 years age;men 45 years age family history pca;men african descent 45 years age;men carrying breast cancer gene 2 (brca2) mutations 40 years age.strongoffer risk-adapted strategy (based initial psa level), follow-up intervals twoyears initially risk:men psa level < 1 ng/ml 40 years age;men psa level < 2 ng/ml 60 years age;postpone follow-up eight years risk.weakstop early diagnosis pca based life expectancy performance status; men life-expectancy < fifteen years unlikely benefit.strong 5.1.6. genetic testing inherited prostate cancer increasing evidence supports implementation genetic counselling germline testing early detection pca management . several commercial screening panels available assess main pca risk genes . however, remains unclear germline testing considered may impact localised metastatic disease management. germline brca1 brca2 mutations occur approximately 0.2% 0.3% general population . important understand difference somatic testing, performed tumour, germline testing, performed blood saliva identifies inherited mutations. genetic counselling required prior undergoing germline testing. germline mutations drive development aggressive pca. therefore, consensus following men, personal family history pca cancer types arising dna repair gene mutations considered germline testing: men metastatic pca candidates targeted treatment;men brca mutations somatic testing;men multiple family members diagnosed cspca age < 60 years family member died pca;men family history high-risk germline mutations family history multiple cancers side family. research field (including well-known germline mutations) needed develop screening, early detection treatment paradigms mutation carriers family members. 5.1.7. guidelines germline testing* recommendationsstrength ratingconsider germline testing men multiple family members diagnosed pca age < 60 years family member died pca.weakoffer germline testing men family history high-risk germline mutations family history multiple cancers side family.strongoffer germline testing patients breast cancer gene (brca) mutations somatic testingstrong *genetic counselling required prior germline testing.